Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIRMATION-HF
2023-508874-27-00Phase 3Authorised
- Sponsor
- CPC Clinical Research
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised trial of empagliflozin and finerenone in heart failure (HF) and Acute Heart Failure (AHF) (2 arms), sponsored by CPC Clinical Research. Primary endpoint: Clinical benefit hierarchical composite. Planned start Oct 2025; status: authorised.
02
Drugs
empagliflozinfinerenone
03
Conditions
heart failure (HF)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2023-508874-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508874-27-00.